MITO Projected Dividend Yield

ADS (Sponsored)/Stealth BioTherapeutics Corp ( NASDAQ : MITO )

Stealth BioTherapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies for diseases involving mitochondrial dysfunction. Co.'s first clinical product candidate, elamipretide, is a small peptide that targets and binds reversibly to cardiolipin, an essential structural element of mitochondria, stabilizing the inner mitochondrial membrane under conditions of oxidative stress. Co.'s second clinical product candidate, SBT-272, is a peptidomimetic that has been shown to increase adenosine triphosphate production and decrease levels of reactive oxygen species in dysfunctional mitochondria in preclinical studies.

20 YEAR PERFORMANCE RESULTS